The susceptibility of four isolates of Schistosoma mansoni (BH, MAP, MPR-1 and K) to four multiple doses of anti-schistosomal agents (hycanthone, niridazole, oxamniquire, and praziquantel) were evaluated in infected female Swiss albino mice. These schistosomal isolates had been maintained in the laboratory without further drug pressure for 20 to 30 generations. Multiple dosage regimens were used for each drug against each isolate of S. mansoni to generate ED50 (effective dose 50%) values. Results demonstrated that the K isolate is resistant to niridazole, the MPR-1 isolate to oxamniquine, and the MAP isolate to both hycanthone and oxamniquine. The BH isolate was susceptible to all drugs and was used as the reference isolate. All isolates were susceptible to praziquantel. The significance of the difference in response of the MPR-1 and MAP isolates is discussed. These results confirm the resistance of these isolates of S. mansoni of three schistosomicides and demonstrate that the resistance of these isolates are stable over long periods of time without exposure to drugs.

Camundongos infectados experimentalmente com Schistosoma mansoni foram tratados por via oral com dose única de 125 ou 250 mg/kg de oltipraz, 50 ou 100 mg/kg de oxamniquine, e 200 ou 400 mg/kg de praziquantel. O número de vermes e alteração do oograma foram determinados entre a 1ª e 16ª semanas após o tratamento. O tempo necessário para observar o máximo de atividade da droga foi de 1 semana para o praziquantel, 2 semanas para o oxamniquine e 8 semanas para o oltipraz. Alterações do oograma persistiram durante o período de observação, embora recidiva tenha sido detectada, já na 4ª semana, com as drogas utilizadas.

Mice infected with adult Schistosoma mansoni were dosed with a single oral dose of 125 or 250 mg/kg oltipraz, 50 or 100 mg/kg oxamniquine, or 200 or 400 mg/kg praziquantel. The mortality rate of worms and oogram changes were determined between 1 and 16 weeks after dosing. The time required between dosing and postmortem to obtain maximum effectiveness was 1 week for praziquantel, 2 weeks for oxamniquine and 8 weeks for oltipraz. Changes in oograms persisted throughout most of the experiment, although relapse has been observed at the 4th week on.

Com duas linhagens de Biomphalaria glabrata foi estudada a suscetibilidade de cinco cepas de Schistosoma mansoni resistentes e suscetíveis a esquistossomicidas. Três cepas do trematódeo oriundas de Porto Rico apresentaram desenvolvimento mais lento e menor índice de infecção em B. glabrata brasileira quando comparados com o comportamento de duas cepas de S. Mansoni provenientes do Brasil. Por outro lado, as cepas brasileiras do parasita desenvolve ram bem e infectaram mais de 90% dos exemplares de B. glabrata portorriquenhos. Entre os resultados, ressalta-se que cepas resistentes a esquistossomicidas poderão ser introduzidas por pacientes em diferentes áreas geográficas como Brasil e Porto Rico.

Five strains of Schistosoma mansoni resistant and susceptible to schistosomicides were studied for infectivity of 2 strains of Biomphalaria glabrata one of Puerto Rican origin and the other of Brazilian origin. Puerto Rican strains of S. Mansoni developed more slowly and had a lower infectivity in Brazilian B. glabrata than did the Brazilian S. mansoni. However, Brazilian S. Mansoni developed as well in Puerto Rican snails as in Brazilian snails, indicating that drug resistant strains could easily be moved by travel of infected persons from one area to another.

The BH strain of Schistosoma mansoni was found to be highly susceptible, to hy cant hone (1 x 80 mg/kg), oxamniquine (1 x 100 mg/kg) niridazole (5 x 100 mg/kg), praziquantel (1 x 100 mg/kg), oltipraz (5 x 125 mg/kg) and amoscanate (1 x 300 mg/kg) and is therefore a good reference strain for chemotherapeutic trials. By contrast, the MPR-1 strain was shown to have developed resistance to oxamniquine without ever having been dosed with oxamniquine. Other oxamniquine/hycanthone resistant strains were shown to have maintained their resistance and a strain believed to be partially resistant to oltipraz was evaluated.

Drug resistance associated with the treatment of human schistosomiasis appears to be an emerging problem requiring more attention from the scientific community than the subject currently receives. Drug-resistant strains of Schistosoma mansoni have been isolated by various investigators as a result of laboratory experimentation or from a combination of field and laboratory studies. Review of this data appears to indicate that the lack of susceptibility observed for some of the isolated strains cannot be ascribed solely to previous administration of antischistosome drugs and thus further studies are required to elucidate this phenomena. Strains of S. mansoni have now been identified from Brazil which are resistant to oxamniquine, hycanthone and niridazole; from Puerto Rico which are resistant to hycanthone and oxamniquine; and from Kenya which are resistant to niridazole and probably oxamniquine. Strains derived by in vitro selection and resistant to oxamniquine and possibly to oltipraz are also available. All of these strains are currently maintained in the laboratory in snails and mice, thus providing for the first time an opportunity for indepth comparative studies. Preliminary data indicates that S. haematobium strains resistant to metrifonate may be occurring in Kenya. This problem could poise great difficulty in the eventual development of antischistosomal agents. Biomphalaria glabrata from Puerto Rico and Brazil were found to be susceptible to drug-resistant S. mansoni from each country.